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Induction of plasminogen activator inhibitor type 1 in murine lupus-
like glomerulonephritis. Three major components of the plasminogen
activators (PA)/plasmin system are synthesized physiologically in glomer-
uli, and can be involved in glomerular proteolysis and extracellular matrix
metabolism: tissue-type PA (tPA), urokinase (uPA) and PA inhibitor type
1 (PAl-i). To explore the possible role of a dysregulation of the plasmin
protease system in the development and progression of lupus-like glomer-
ulonephritis, we studied the expression of the renal plasmin protease
components during the course of the disease, either acute, induced by
IgG3 monoclonal cryoglobulins, or chronic, occurring spontaneously in
three different lupus-prone mice: (NZBxNZW)FI, BXSB and MRL-lpr/
lpr. RNase protection assays and in situ hybridizations revealed a marked
glomerular induction of PAT-i mRNA abundance without any significant
changes in renal tPA and uPA mRNA levels in the two different types of
lupus-like glomerulonephritis. The overexpression of PAT-i mRNA oc-
curred in parallel with a significant decrease in glomerular tPA-catalyzed
enzymatic activity as determined by zymographic analysis. In addition, a
concomitant increase in glomerular expression of transforming growth
factor /31 (TGF-131) mRNA was observed. The demonstration of a close
correlation between the PAL-i and TGF-/31 mRNA levels and the severity
of lupus-like glomerular lesions suggests that a perturbation of the
glomerular PA/PA! balance, resulting from a marked TGF-j3i-mediated
induction of PAl-i gene expression, plays an important role in the
progression of lupus-like glomerular lesions, leading to glomerulosclerosis.
Glomeruloscierosis is characterized by an accumulation of
extracellular matrix (ECM) as a result of an excessive production
and/or an insufficient degradation of ECM. This process is
considered to be the final pathogenetic pathway leading to the
progressive loss of renal function in a number of glomerulopathies
including lupus nephritis. Although the molecular basis for the
development of glomerulosclerosis remains unclear, it has been
proposed that a dysfunction in glomerular coagulation and pro-
teolysis may play a role in this process [1—7]. Fibrin deposits may
promote glomerular injuries by occluding capillaries, by promot-
ing inflammatory cell migration and glomerular cell proliferation,
and by a direct cytotoxic effect on mesangial cells [8]. This is
further supported by the fact that anticoagulant treatment pre-
vents the development of glomeruloscierosis in an experimental
model of glomerulonephritis [9].
It is now well documented that three major components of the
plasminogen activators (PA)/plasmin system—tissue-type PA
(tPA), urokinase (uPA) and PA inhibitor type I (PAI-1)—are
expressed in glomeruli under physiological and pathological con-
ditions [10—13]. Since PAs and their inhibitors play an important
role in fibrinolysis and in ECM degradation, a diminished synthe-
sis of glomerular PA and/or an increased production of glomer-
ular PAl following primary glomerular injuries may result in an
imbalance in the extracellular proteolytic process, thereby leading
to the generation of glomerular sclerotic lesions.
To explore the possible role of a dysregulation of the plasmin
protease system in the development and progression of lupus-like
glomerulonephritis, we have studied the expression of the renal
plasmin protease system during the course of acute lupus-like
glomerulonephritis induced by murine IgG3 monoclonal cryo-
globulins [14—161 and of chronic glomerulonephritis occurring
spontaneously in three different strains of lupus-prone mice:
(NZBxNZW)F1, BXSB and MRL-lpr/lpr [17]. In parallel, we
determined the renal mRNA expression of transforming growth
factor 131 (TGF-pI) for two reasons. First, it has been shown that
TGF-p1 decreases the synthesis of proteases, including tPA and
uPA, and induces the production of PAT-i both in vitro and in vivo
[18—25]. Second, TGF-p1 appears to play a crucial role in the
development of glomerulosclerosis in experimental anti-Thy-i
glomerulonephritis and diabetic nephropathy [26, 27]. Our results
indicate that a marked induction of PAl-i and TGF-/31 gene
expression in glomeruli is associated with the progression of
glomerulonephritis in these different experimental models of
murine lupus nephritis.
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Mice
BALB/c and C57BL/6 mice were obtained from Bomholtgard
Ltd. (Ry, Denmark). (NZBxNZW)F1, BXSB, MRL-lpr/lpr and
MRL-+/+ mice were purchased from Harlan Olac Ltd. (Oxon,
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Fig. 1. Histology of glomerular lesions in MRLXBALB mice injected with hybridoma cells secreting 6—19 IgG3 anti-lgG2a RF mAb. A total of io hybridoma
cells were injected i.p. into pristane-treated MRLxBALB mice on day 0, and three mice were sacrificed at days 0, 3, 5 and 7 after the injection of
hybridoma cells. A-B. Normal appearance of glomeruli at days 0 and 3 (PAS, X200). C. Representative histological appearance of glomerular lesions
in mice sacrificed at day 5. Note the infiltration of polymorphonuclear leukocytes and increased glomerular cellularity (PAS, X200). D. Representative
histological appearance of glomerular lesions at day 7. Leukocyte exudation is less prominent. Note the presence of PAS-positive deposits along the
glomerular capillary walls, resembling "wire-loop" lesions (PAS, )<200).
UK). (MRL-+/+ x BALB/c)F1 hybrid (MRLxBALB) mice were RF), 7B6.8 (anti-DNA) and 2—2G (unknown specificity)] were
bred in our own animal facilities, obtained from unmanipulated MRL-lprllpr mice [14, 15, 28].A
non-cryogenic IgG3 anti-dinitrophenyl mAb (9A6) was estab-Monoclonal antibodies lished from BALB/c mice immunized with dinitrophenyl-lipopoly-
Murine 1g03 monoclonal antibodies (mAb) with cryoglobulin saccharide [29]. The 6—19 1gM class switch variant lacking cryo-
activity [6—19, 1—10B4 and AM16 (anti-lgG2a rheumatoid factor; globulin activity was obtained by transfecting 6—19 heavy-chain
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Fig. 2. RNase protection analysis of PA 1-1, IPA,
uPA and GAPDH mRNA in kidneys from mice
injected with hybridoma cells secreting 6—19 IgG3
anti-IgG2a RF mAb. Mice were sacrificed at
days 0, 3, 5 and 7 after the injection of
hybridoma cells. Five micrograms of total
kidney RNA from three mice at each time
point were individually analyzed for the
presence of PAl-I, tPA, uPA and GAPDH
mRNA using corresponding cRNA probes.
Fig. 3. Localization of PAl-i mRNA
accumulation (A) and of tPA -catalyzed enzymatic
activity (B) on kidney sections from mice injected
with hybridoma cells secreting 6—19 IgG3 anti-
IgG2a RF mAb. Cryostat kidney sections from
6—19 hybridoma-injected mice at days 0, 3, 5
and 7 were analyzed by in situ hybridization
with 32P-labeled PAT-i cRNA probe (A) and by
in situ zymographies in the presence of 1 mM
amiloride, which selectively inhibits uPA
catalytic activity and therefore allows the
identification of tPA-catalyzed enzymatic
activity (B). Note that PAl-i mRNA, which is
not detectable at day 0 (DO) and day 3 (D3), is
exclusively localized in the cortex at day 5 (D5)
and day 7 (D7) with a speckled pattern,
suggesting a glomerular localization, and that
increased glomerular PAT-i mRNA
accumulation paralleled with a reduction of
caseinolysis over glomerular structures, as
compared with that of day 0.
loss mutant cell line with the VDJH6—i9-C.r plasmid. The 6—19 Histological studies
IgGi switch variant without cryoglobulin activity was established Samples of kidney tissues were fixed in 10% formalin, and
by sequential sublining [16]. A total of io hybridoma cells were sections were stained with hematoxylin and eosin, periodic acid-
injected i.p. into three-month-old pristane-treated MRLxBALB Schiff (PAS), and phosphotungstic acid reagent to evidence fibrin
mice. Mice were sacrificed three, five and seven days after the deposition. Glomerular lesions in lupus-prone mice were scored
injection of 6—19 hybridoma cells, and between 7 and 10 days for on a 0 to 4+ scale based on the intensity and extent ofhistopatho-
other hybridoma cells. logical changes, according to Pirani and Salinas-Madrigal [30]. A
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Fig. 4. Quantitative analysis of PAl-i (A) and TGF- j31 (B) versus GAPDH
mRNA abundance in kidneys from mice injected with different hybridoma
cells. Mice were injected with cells secreting the following mAb: IgG3
6—19 RF, 6—19 IgGi and 1gM class switch variants, IgG3 RF (1—10B4 and
AM16), IgG3 anti-DNA (7B6.8), IgG3 2-2G (unknown specificity) and
IgG3 anti-dinitrophenyl (9A6). Animals were sacrificed 7 to 10 days later.
PAT-i, TGF-131 and GAPDH mRNA were analyzed in individual mice (2
to 8 mice for each mAb) by the RNase protection assay using PAl-i,
TGF-f31 and GAPDH cRNA probes simultaneously. The intensity of each
signal was quantified by phosphor imager analysis, and results are
expressed as a ratio of the radioactivity associated with the PAl-i or
TGF-131 signal relative to that of the GAPDH signal in individual animals.
grade of 0 was given to kidneys without glomerular lesions. Grade
1 + lesions corresponded to minimal thickening of the mesan-
gium, 2 + lesions contained noticeable increases in glomerular
cellularity, 3 + lesions were characterized by the preceding condi-
tions with superimposed inflammatory exudates and capsular
adhesions, and in 4+ lesions the glomerular architecture was
obliterated in >70% of glomeruli, and tubular cast formation was
extensive. Grades 3 and 4 glomerulonephritis were considered
significant contributors to clinical disease and/or death.
Probe preparations
Complementary and sense RNA probes were transcribed in
vitro as previously described [131 with T3 or T7 RNA polymerase
using murine uPA, tPA, PAl-i and PAI-2 cDNA-containing
plasmids as templates. The TGF-/31 antisense probe was prepared
from pBSKS-TGF-/31 containing the 557 bp EcoRI-KpnI frag-
ment of the murine TGF-pl eDNA, linearized with XbaI for in
situ hybridizations and with BamHI for RNase protection assays.
The murine glyceraldehyde-3-phosphate-dehydrogenase (GAPDH)
antisense RNA probe was synthesized using pGAPDH as tem-
plate. This plasmid contained 260 bp (bases 1 to 260) of the
murine GAPDH cDNA [311.
RNase protection assay
Five micrograms of total RNA extracted from whole kidneys
[32] were hybridized for 16 hours with 300,000 cpm (108 cpm/jg)
c432P]-UTP of various antisense riboprobes at 42°C in 30 itI of
buffer containing 80% formamide, 0.4 M NaCl, 40 m Pipes (pH
6.4), 2 mM EDTA. Yeast tRNA was used as control. After
hybridization, 300 jtl of 0.3 M NaCl, 10 mM Tris (pH 7.4), 4 mM
EDTA, 20 g/ml RNase A were added to the hybridization
mixture and the incubation was continued for 60 minutes at 25°C.
Twenty microliters of proteinase K at 0.5 mg/ml and 20 d of SDS
at 10 mg/mI were added, and the mixture further incubated at
35°C for 20 minutes. RNA hybrids were then extracted with
phenol-chloroform and precipitated with ethanol. The pellets
were resuspended in 8 jl RNA-loading buffer (80% formamide, 1
mM EDTA, 0.1% bromophenol blue and 0.1% xyiene-cyanol) and
samples loaded on a 16 >< 20 cm 8 M urea-6% polyacrylamide gel
and electrophoresed at 15 V/cm for three hours. After electro-
phoresis, the gel was fixed with acetic acid/ethanol/water (1:2:7),
dried and exposed to autoradiographic film (Kodak X-Omat film,
Eastman Kodak, Rochester, NY, USA) and/or phosphor images
screen for counting (Image Quant Software FAST SCAN, Mo-
lecular Dynamics Ltd, Kemsing, UK) [33].
In situ hybridization
Kidneys were frozen in methyl butane and kept at —70°C until
analyzed. Five micrometer cryostat tissue sections were fixed in
4% glutaraldehyde in PBS for one minute. The hybridization and
post-hybridization washes were carried out as described [111.
Macroscopic mRNA localizations were revealed by film autora-
diography (SB5; Eastman Kodak) after exposure varying from 7
to 14 days.
In situ zymography
Unfixed cryostat tissue sections were overlaid as described [31
with a mixture containing 0.5 ml of a 8% commercial instant
nonfat dry milk solution, 0.75 ml of PBS (with 0.9 mM Ca2 and
1 mM Mg2), 0.7 ml of a 2.5% agar solution in water, 20 jil of a
4 mg/mi solution of purified human plasminogen, and 1 mivi
amiloride which selectively inhibits uPA catalytic activity and
therefore allows the identification of tPA-catalyzed enzymatic
activity. The zymograms were allowed to develop at 37°C for 30
minutes to nine hours. Photographs were taken eight hours after
incubation of zymograms at 37°C using dark-ground illumination.
Statistical analysis
Statistical analysis was performed with the Wilcoxon two-
sample test and the regression test. Probability values <0.05 were
considered significant.
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Fig. 5. Localization of TGF-131 mRNA on
kidney sections from mice injected with
hybridoma cells secreting 6—19 JgG3 anti-IgG2a
RF mAb. Cryostat kidney sections from 6—19
hybridoma-injected mice at days 0, 3, 5 and 7
were hybridized with 32P-labeled TGF-131
cRNA probe. Although the TGF-131 mRNA is
detectable throughout the kidney at day 0 (DO)
and day 3 (D3), its cortical expression with a
speckled reinforcement at day 5 (D5) and day 7
(D7) is markedly enhanced, suggesting a
selective glomerular up-regulation of TGF-pl
mRNA following the injection of 6—19
hybridoma cells.
Results
Induction of PAl-i mRNA in acute lupus-like glomerulonephritis
elicited by 6—19 anti-IgG2a RF mAb
MRLXBALB mice injected with hybridoma cells secreting 6—19
IgG3 anti-IgG2a RF mAb developed acute diffuse glomerulone-
phritis [15]. Initial glomerular lesions (5 days after the implanta-
tion of 6—19 hybridoma cells) consisted of infiltration with poly-
morphonuclear leukocytes, and by day 7 the majority of glomeruli
showed PAS-positive deposits along the capillary walls, resem-
bling "wire-loop" lesions characteristic of lupus nephritis (Fig. 1).
These lesions were accompanied by fibrin deposits admixed in
intraluminal thrombi obstructing the capillary lumen.
To determine whether the development of lupus-like glomeru-
lar lesions induced by 6—19 RF mAb was associated with modu-
lations in renal PA (tPA and uPA) and PAl (PAl-i and PAI-2)
mRNA abundance, whole kidneys were analyzed by RNase
protection assays. Both tPA and uPA mRNA were detected in
control pristane-treated mice, whereas PAl-i and PAI-2 mRNA
were not detectable. The major modulation was observed with
PAl-i mRNA expression: five days after the 6—19 hybridoma cells
injection, kidneys contained high levels of PAl-i mRNA, which
was still undetectable at day 3 (Fig. 2). Comparative measure-
ments of PM-i and GAPDH mRNA levels, as determined by
phosphor imager analysis, showed an —20-fold higher abundance
of PAT-i mRNA five and seven days after the 6—19 hybridoma
injection than in control mice. In contrast, tPA and uPA mRNA
levels did not undergo significant changes following 6—19 hybrid-
oma injection. PAI-2 mRNA was not detectable in 6—19 hybrido-
ma-injected mice (data not shown).
Glomerular localization of PAl-i mRNA in acute lupus-like
glomerulonephritis induced by 6—19 anti-IgG2a RF mAb
The sites of PAl-i mRNA accumulation were localized by
hybridizing kidney sections to a 32P-labeled PAT-i cRNA probe.
PAl-i mRNA was detected exclusively in the cortex at days 5 and
7 following the 6—19 hybridoma cells injection, with speckled
signals indicating a glomerular localization as demonstrated pre-
viously [ii] (Fig. 3A). No PAl-i mRNA was detected in mice
sacrificed at day 3 or in control pristane-treated mice. In contrast,
cortical and medullary patterns of tPA and uPA mRNA accumu-
lation in 6—19 hybridoma-injected mice were essentially identical
to those seen in control mice (data not shown). No PAI-2 mRNA
accumulation was detected following the 6—19 hybridoma injec-
tion (data not shown). Notably, zymographic analysis of kidney
cryostat sections revealed a significant decrease in tPA-catalyzed
glomerular enzymatic activity five days after the 6—19 hybridoma
injection (Fig. 3B), which paralleled with an increased glomerular
PAl-i mRNA accumulation.
Induction of PAl-i mRNA following injection of nephritogenic
IgG3 monoclonal ciyoglobulins
To determine whether the accumulation of PAl-i mRNA in
kidneys from mice receiving 6—19 hybridoma cells was associated
with the development of lupus-like glomerular lesions, the effect
of mAb with or without nephritogenic activities was explored. For
this purpose, we assessed the capacity of the 6—19 IgGi and 1gM
class switch variants to induce glomerular PAl-i mRNA expres-
sion. Both 6—19 Ig class switch variants, which generate neither
cryoglobulins nor glomerular lesions [16], completely failed to
induce significant expression of PAl-i mRNA in kidneys (Fig.
4A), excluding an effect of hybridoma cell injections on renal
PAl-i mRNA accumulation.
In addition, we compared the effect of three nephritogenic
IgG3 monoclonal cryoglobulins [two RF mAb (1—10B4 and
AM16) and one anti-DNA mAb (7B6.8)] with two non-nephrito-
genie IgG3 mAb (2—2G cryogenic and 9A6 non-cryogenic mAb)
[14, 15, 28]. The three nephritogenic mAb, which generate
"wire-loop" lupus-like glomerular lesions independently of their
specificities, again induced renal PAl-i mRNA, although to levels
lower than those induced by 6—19 RF mAb (Fig. 4A). It should be
mentioned that glomerular lesions induced by the former three
mAb were somehow less severe than those caused by 6—19 RF
mAb [14, 15, 28]. In contrast, only minimal or little induction of
renal PAT-i mRNA was observed with two non-nephritogenic
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NZB x NZW BXSB
Fig. 6. RNase protection analysis of PAl-I, TGF-3I and GAPDH mRNA in kidneys from three different strains of lupus-prone mice: (NZBxNZW)Fi, BXSB
and MRL-lpr/lpr. Total RNA of kidneys from lupus-prone and non-autoimmune (C57BL/6) mice of different ages were analyzed by the RNase
protection assay using PAT-i, TGF-131 and GAPDH cRNA probes simultaneously; three different RNase-protected bands (319 bp for PAl-i, 140 bp
for TGF-/31 and 260 bp for GAPDH) are revealed. RNA extracted from yeast (*) was used as a negative control in each assay. nb = newborn.
IgG3 mAb (2—2G arid 9A6). Notably, no significant changes in
renal PA mRNA levels were observed with these five IgG3 mAb,
independently of their nephritogeriic activities (data not shown).
Enhanced accumulation of TGF-/31 mRNA in acute lupus-like
glomenilonephritis induced by IgG3 monoclonal ciyoglobulins
Since TGF-J31 can increase the levels of PAl-I mRNA in vitro
and in vivo 18, 20—22, 24, 25, 35], the renal abundance of TGF-131
mRNA was determined following the injection of 6—19 hybridoma
cells by RNase protection assay. Quantitative analysis, normalized
to GAPDH mRNA levels, revealed that renal TGF-131 mRNA
abundance was increased significantly only seven days after the
6—19 hybridoma injection (mean of 8 mice; 1.6 0.5-fold
increase; P = 0.005; Fig. 4B). No significant up-regulation of
TGF-/31 gene expression was observed in mice receiving 6—19 Ig
class switch variants (6—19 IgGi and 1gM), nephritogenic 1—10B4,
AM16 and 7B6.8 hybridoma cells and non-nephritogenic 2—2G
and 9A6 hybridoma cells.
To define the tissue localization of TGF-131 mRNA up-regula-
tion, kidney sections obtained from mice injected with 6—19
hybridoma cells and control mice were hybridized to the TGF-J31
cRNA probe. Whereas TGF-/31 mRNA transcripts were detected
throughout the kidney in both injected and control animals, the
cortex in 6—19 mAb-injected mice displayed a reinforcement of
speckled signals at days 5 and 7, suggesting a selective glomerular
up-regulation of TGF-131 mRNA expression (Fig. 5). In addition,
a similar cortical reinforcement of the TGF-f31 signal was detected in
the kidneys of mice injected with nephritogenic 1—10B4, AMI6 and
7B6.8 hybridoma cells (data not shown), although RNase protection
assays had failed to show any increase in overall renal TGF-f31
mRNA accumulation (Fig. 4B). In contrast, no specific glomerular
accumulation of TGF-pl mRNA was observed in mice injected
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with 2—2G and 9A6 mAb lacking nephritogenic activities (data not
shown).
Up-regulation of PAl-i and TGF-/31 mRNA expression in
spontaneous chronic lupus nephritis
Using three different strains of lupus-prone mice [(NZBxN-
ZW)F1, BXSB and MRL-lprllpr] renal expression of PAT-i and
TGF-pl mRNA was assessed in relation to the development of
their glomerular lesions. For this purpose, total RNA was ex-
tracted from kidneys of lupus-prone and non-autoimmune
C57BL/6 mice of various ages, and PAl-i, TGF-/31 and GAPDH
mRNA abundance was simultaneously analyzed by RNase pro-
tection assay, in which three different sizes of RNase-protected
bands (319 bp for PAl-i, 140 bp for TGF-pl and 260 bp for
GAPDH) were revealed. All three strains of lupus-prone mice
exhibited an increased abundance of both PAl-i and TGF-f31
mRNA concomitantly with the development of severe glomerular
lesions, that is, at eight to nine months for (NZBxNZW)F1
females and BXSB males, and at four months for MRL-lpr/lpr
females (Fig. 6). This was in marked contrast to the absence of any
changes in the abundance of PAl-I and TGF-131 mRNAs in
female BXSB mice, which failed to develop lupus-like nephritis
during the first year of their life [17], and in non-autoimmune
C57BL/6 mice. Quantitative analysis of PAl-i versus GAPDH and
TGF-pl versus GAPDH mRNA abundance in individual lupus-
prone mice revealed a remarkable correlation between PAl-i and
TGF-f31 mRNA levels (r = 0.688; P < 0.001). Notably, increases
in PAl-i and TGF-131 mRNA levels were highly significant when
the histological grade was >3, which is considered clear evidence
of clinical disease (P < 0.005; Fig. 7).
In situ hybridization studies of PAl-I and TGF-f31 mRNA
accumulation sites in the three lupus-prone strains showed results
essentially identical to those obtained from mice injected with
6—19 mAb. Markedly enhanced accumulation of both PAl-i and
TGF-f31 mRNA was confined to the cortex, with speckled signals
suggesting glomerular localization (Fig. 8). Zymographic analysis
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Fig. 7. Quantitative analysis of renal PAl-i and
TGF-/31 versus GAPDH mRNA abundance in
relation to the intensity of glomerular lesions in
three different strains of lupus-prone mice
(NZBxNZW)Fi, BXSB and MRL-lpr/lpr. Total
RNA of kidneys from lupus-prone and non-
autoimmune (C57BL/6) mice were analyzed by
the RNase protection assay using PAT-i, TGF-
J31 and GAPDH cRNA probes simultaneously.
The ratio of the radioactivity associated with
the PAT-I or TGF-pl signal relative to that of
the GAPDH signal in individual animals was
computed from the intensity of each signal
determined by phosphor imager analysis. PAT-l/
GAPDH mRNA and TGF-/31/GAPDH mRNA
ratios were correlated with the severity of
glomerular lesions, expressed as histological
grades based on the intensity and extent of
histopathological changes, in individual animals.
3 4
Histological grades
PAl-i TGF- Zymography
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Fig. 8. Loca!ization of PAl-I and TGF- /31 mRNA accumu!ation and of tPA-cata!yzed enzymatic activity in nephritic kidneys from three different strains of
!upus-prone mice (NZBxNZW)Fi, BXSB and MRL-!pr/!pr. Ciyostat kidney sections from lupus-prone and non-autoimmune (C57BL/6) mice were
analyzed by in situ hybridization with 32P-labeled PAl-i or TGF-/31 cRNA probe and by zymographies in the presence of 1 m'vi amiloride. Note a marked
induction and/or up-regulation of PAT-i and TGF-/31 mRNA accumulation with a speckled glomerular localization, which parallels with the decrease
in tPA-catalyzed caseinolysis over glomerular structures in diseased kidneys from three different lupus mice Strains.
revealed a decrease in tPA-catalyzed enzymatic activity over
glomerular structures in diseased kidneys from the three different
lupus mice.
Discussion
In the present study, we have demonstrated a perturbation of
the glomerular PAJPAI balance as a result of a marked induction
of PAl-i gene expression during the course of lupus-like glomer-
ulonephritis, either induced by IgG3 monoclonal cryoglobulins or
occurring spontaneously in three different strains of lupus-prone
mice: (NZBxNZW)F1, BXSB and MRL-!pr/lpr. In addition, we
observed that the induction of PAT-i mRNA occurred in parallel
with an increased glomerular expression of TGF-/31 mRNA. The
demonstration of a close correlation between the PAl-I and
TGF-/31 mRNA levels and the severity of glomerular lesions
suggests that PAl-i as well as TGF-f31 may play an important role
in the progression of lupus-like glomerular lesions, leading to
glomerulosclerosis. The lack of PAl-i and TGF-/31 mRNA induc-
tion in mice receiving hybridoma cells producing non-nephrito-
genic mAb further supports the association of PAl-i and TGF-J31
induction with the development and progression of lupus-like
glomerulonephritis.
It is significant that, during the course of lupus-like glomerulo-
nephritis, the glomerular expression of the PAl-i gene was
selectively induced without any detectable concomitant changes in
tPA and uPA gene expression. Since PAT-i is a specific inhibitor
of tPA and uPA [36—381, a glomerular overexpression of PAl-i
may contribute to the glomerular deposition of fibrin and to the
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progressive pathological accumulation of ECM occurring in lupus
nephritis, leading to renal failure. Enzymatic analysis further
confirmed a decrease of glomerular tPA-catalyzed enzymatic
activity both in acute lupus-like glomerular lesions induced by
IgG3 monoclonal cryoglobulins and in lupus-prone mice exhibit-
ing severe glomerular lesions.
The glomerular localization of PAl-i mRNA, as indicated by in
situ hybridization experiments, suggests that PAl-I may be syn-
thesized by inflammatory cells infiltrating glomeruli or by glomer-
ular mesangial cells [12] and/or endothelial cells as demonstrated
recently by Keeton et a! in MRL-lpr/lpr mice [39]. Since PAl-i
expression is not detectable in glomeruli under physiological
conditions, if resident glomerular cells in nephritic lesions are the
sites of PAT-i mRNA accumulation, this could be mediated by
cytokines locally released by infiltrating PMN and other inflam-
matory cells and/or by activated glomerular cells. In this regard,
the concomitant increase in glomerular expression of TGF-131 is
noteworthy, since this cytokine is a potent inducer of PAT-i
biosynthesis in vitro and in vivo [22, 24, 25]. It should be
emphasized that an increased glomerular expression of TGF-f31
mRNA in diseased glomeruli could be detected by in situ hybrid-
ization, even when RNase protection assays on total kidney RNA
failed to demonstrate any significant up-regulation in overall renal
TGF-j31 mRNA accumulation. This is, for instance, the case for
mice injected with 1—10B4, AM16 and 7B6.8 hybridoma cells and
for mice sacrificed five days after injection with 6—19 anti-IgG2a
RF hybridoma cells. This discrepancy is likely to be related to the
fact that glomeruli contain only a minor portion of the overall
renal TGF-/31 mRNA.
That the levels of PAT-i and TGF-J31 mRNAs in mice receiving
1—10B4, AMI6 and 7B6.8 mAb are lower than those in 6—19
mAb-injected mice is likely to be related to the fact that the
former mAb induce milder glomerular lesions than the 6—19 mAb
[14, 15, 28]. This is consistent with the finding that the increases in
PAl-i and TGF-131 mRNA levels correlated very well with the
severity of glomerular lesions spontaneously occurring in the
three different lupus-prone mice. Taken together, our results
suggest a model in which early events in the pathogenetic cascade
of lupus nephritis cause an increase in glomerular TGF-131
expression, the cytokine in turn inducing a dramatic local increase
in PAl-i production; this would result in an inhibition of prote-
olysis and an accumulation of ECM, thereby actively participating
in the process of glomerulosclerosis. This is consistent with
observations from other laboratories in two different experimental
models of glomerulonephritis (anti-Thy-I antibody-induced me-
sangial proliferative glomerulonephritis and anti-glomerular base-
ment membrane antibody-induced glomerulonephritis) [40, 411.
In conclusion, we suggest that an increased expression of
TGF-/31 and PAl-i may be involved in the progression of
glomerular lesions during the course of acute and chronic lupus-
like glomerulonephritis. The remarkable induction of PAl-i
mRNA in association with the development and progression of
lupus-like glomerulonephritis does not necessarily imply that
PAl-i is a major factor in the process of generating glomerular
sclerotic lesions. The participation of other proteases and/or their
inhibitors cannot be excluded in this process. This question can be
answered in studies on mice deficient in PAl-i [42], which are in
progress in our laboratory. The relative contribution of TGF-pI to
glomerulosclerosis and the identification of the cellular sources of
TGF-f31 and PAT-i are other important questions that need to be
answered. Obviously, further elucidation of cellular and molecular
events involved in the progression of glomerulonephritis would
help design new therapeutic approaches for lupus nephritis and
other glomerular pathologies.
Acknowledgments
This work was supported by grants from the Swiss National Foundation
for Scientific Research. We thank Ms. Genevieve Leyvraz for histological
processing of kidneys, and Mr. J.C. Rumbeli and Mr. E. Denkinger for
photograph work.
Reprint requests to Shozo Izui, M.D., Department of Pathology, C.M. U.,
1211 Geneva 4, Switzerland.
Appendix
Abbreviations are: ECM, extracellular matrix; PA, plasminogen activa-
tor; tPA, tissue-type PA; uPA, urokinase; PAT-i, PA inhibitor type 1;
TGF-1, transforming growth factor 1; mAb, monoclonal antibody; RF,
rheumatoid factor; PAS, periodic acid-Schiff; GAPDH, glyceraldehyde-3-
phosphate-dehydrogenase.
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